Method for treating cystic fibrosis
View Patent ↗The present invention is directed to a method for treating cystic fibrosis. The method comprises the steps of: identifying a patient suffering from cystic fibrosis, and administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide. In one method, denufosol and the macrolide are administered by inhalation, preferably in a single formulation. In another method, denufosol is administered by inhalation and the macrolide is administered orally. The present invention is also directed to a pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier. Preferred denufosol is denufosol tetrasodium and preferred macrolide is azithromycin. The pharmaceutical formulation preferably is in a form of an inhalable dry powder or in a liquid form.
1. A method for treating cystic fibrosis, comprising the steps of:
identifying a patient suffering from cystic fibrosis,
administering to the patient an effective amount of denufosol or a pharmaceutically acceptable salt thereof and an effective amount of a macrolide.
2. The method according to claim 1 , wherein the denufosol is administered by inhalation.
3. The method according to claim 2 , wherein the macrolide is administered by oral administration or inhalation.
4. The method according to claim 1 , wherein said denufosol is denufosol tetrasodium.
5. The method according to claim 1 , wherein said denufosol and the macrolide are co-administered.
6. The method according to claim 1 , wherein said denufosol and the macrolide are co-administered in a single pharmaceutical formulation by inhalation.
7. The method according to claim 1 , wherein said macrolide is selected from the group consisting of azithromycin, clarithromycin, dirithromycin, erythromycin, and roxithromycin.
8. The method according to claim 7 , wherein said macrolide is azithromycin.
9. The method according to claim 1 , wherein the effective amount of denufosol is about 100-400 mg per day and an effective amount of a macrolide is 10-200 mg per day.
10. A pharmaceutical formulation comprising denufosol or a pharmaceutically acceptable salt thereof, a macrolide, and a pharmaceutically acceptable carrier.
11. The pharmaceutical formulation according to claim 10 , wherein said denufosol is denufosol tetrasodium and said macrolide is azithromycin.
12. The pharmaceutical formulation according to claim 10 , which is in a form of an inhalable dry powder.
13. The pharmaceutical formulation according to claim 12 , comprising about 30-130 mg of denufosol tetrasodium and about 3-70 mg of azithromycin in a unit dosage form.
14. The pharmaceutical formulation according to claim 10 , which is in a liquid form.
15. The pharmaceutical formulation according to claim 14 , comprising about 5-50 mg/mL of denufosol tetrasodium and about 0.5-8 mg/mL of azithromycin.